Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
In August 2025, Wegovy became the first GLP-1 receptor agonist approved for treating MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis in adults without cirrhosis
There were no significant correlations between changes in body weight and kidney function parameters
The maximum-to-minimum glucose ratio (MMGR) was calculated to evaluate plasma glucose variation (maximum glycemic value minimum glycemic value, during the MMTT)
10.1016/j.ejphar.2018.09.030 100 LiuX.XavierC.JannJ.WuH
US$ 26.34
US$ 29.28
US$ 27.05
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 29.54
